These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1399828)

  • 1. Potentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea's toxicity in vitro by two new bioreductive agents.
    Papadopoulou MV; Mainwaring A; Bloomer WD
    Jpn J Cancer Res; 1992 Aug; 83(8):907-13. PubMed ID: 1399828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiosensitization and hypoxic cell toxicity of NLA-1 and NLA-2, two new bioreductive compounds.
    Papadopoulou MV; Epperly MW; Shields DS; Bloomer WD
    Jpn J Cancer Res; 1992 Apr; 83(4):410-4. PubMed ID: 1506276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of toxicity from N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea in V79 spheroids by a nitrofuran.
    Durand RE; Olive PL
    Cancer Res; 1987 Oct; 47(20):5303-9. PubMed ID: 3652036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemosensitization of CCNU in KHT murine tumor cells in vivo and in vitro by the agent RB 6145 and its isomer PD 144872.
    Siemann DW
    Radiother Oncol; 1995 Jan; 34(1):47-53. PubMed ID: 7792398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-1,2,3,4-tetrahydroacridine hydrochloride. A novel DNA-affinic hypoxic cell cytotoxin and radiosensitizer. Comparison with NLA-1.
    Papadopoulou MV; Rosenzweig HS; Doddi M; Bloomer WD
    Oncol Res; 1994; 6(9):439-48. PubMed ID: 7703530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nitroimidazole-based bioreductive compounds bearing a quinazoline or a naphthyridine chromophore.
    Papadopoulou MV; Bloomer WD
    Anticancer Drugs; 2009 Jul; 20(6):493-502. PubMed ID: 19430289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Misonidazole-induced chemopotentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea toxicity in O6-methylguanine-DNA methyltransferase proficient (Mer+) and deficient (Mer-) cell lines.
    Mulcahy RT
    Cancer Res; 1986 Jun; 46(6):2892-7. PubMed ID: 3698015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) toxicity by acetohydroxamic acid analogues of 3-nitropyrazole in vitro.
    Mulcahy RT; Wustrow DJ; Hark RR; Kende AS
    Invest New Drugs; 1987; 5(3):281-7. PubMed ID: 3667163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer.
    Papadopoulou MV; Ji M; Rao MK; Bloomer WD
    Oncol Res; 1996; 8(10-11):425-34. PubMed ID: 9114435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo potentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea by the radiation sensitizer benznidazole.
    Siemann DW; Morrissey S; Wolf K
    Cancer Res; 1983 Mar; 43(3):1010-3. PubMed ID: 6825075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): a novel DNA-affinic bioreductive agent as chemosensitizer. I.
    Papadopoulou MV; Ji M; Rao MK; Bloomer WD
    Oncol Res; 1997; 9(5):249-57. PubMed ID: 9306432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary evaluation of isocyanate-generating nitroheterocycles as chemosensitizers, radiosensitizers and hypoxic cell cytotoxic agents.
    Mulcahy RT; Wustrow DJ; Kende AS
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1609-13. PubMed ID: 6548210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain.
    Hirst DG; Brown JM; Hazlehurst JL
    Br J Cancer; 1982 Jul; 46(1):109-16. PubMed ID: 7201845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NLA-1: a 2-nitroimidazole radiosensitizer targeted to DNA by intercalation.
    Denny WA; Roberts PB; Anderson RF; Brown JM; Phil D; Wilson WR
    Int J Radiat Oncol Biol Phys; 1992; 22(3):553-6. PubMed ID: 1735695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of CCNU activity by misonidazole in metastases.
    Siemann DW; Alliet KL
    Clin Exp Metastasis; 1987; 5(1):57-63. PubMed ID: 3829497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms involved in the potentiation of melphalan by the bioreductive compound THNLA-1 in vitro.
    Papadopoulou MV; Ji M; Khan SH; Bloomer WD
    Oncol Res; 1999; 11(8):345-57. PubMed ID: 10803738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo combination of misonidazole and the chemotherapeutic agent CCNU.
    Siemann DW
    Br J Cancer; 1981 Mar; 43(3):367-77. PubMed ID: 7225287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure/activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNU.
    Workman P; Twentyman PR
    Br J Cancer; 1982 Aug; 46(2):249-59. PubMed ID: 7150475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-link formation and chemopotentiation of EMT-6/Ro cells exposed to MISO after CCNU treatment in vitro.
    Mulcahy RT
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1389-92. PubMed ID: 3759561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice.
    Lee AE; Wilson WR
    Toxicol Appl Pharmacol; 2000 Feb; 163(1):50-9. PubMed ID: 10662604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.